LivingGLP1
Study S000596

Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase

Registration

Registration
NCT05313529
Acronym
LIGHT-MCI
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Status
COMPLETED
Enrollment
396
Start
2022-10-08
Primary completion
2025-12-31
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions
Type 2 Diabetes Mellitus; Mild Cognitive Impairment
Interventions
DRUG:Liraglutide; DRUG:Empagliflozin; DRUG:Linagliptin
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • Mild cognitive impairment (MCI) remission rate [The core study spans from baseline to 48 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0018433Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.
Yu C, BMJ open
2025ProtocolPMID 40840993DOIcites ClinicalTrials.gov:NCT05313529; registry reference DERIVED:40840993
R0022403Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Cheng H, Diabetes care
2022Randomized trialPMID 35263425DOIregistry reference RESULT:35263425
R0011068Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Zhang Z, Diabetes care
2019OtherPMID 31221697DOIregistry reference RESULT:31221697